Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022)
Fennec Pharmaceuticals' (FENC) quarterly Short term Debt came in at $25.0 million in Q4 2022, up 1263.88% YoY from $1.8 million in Q4 2021, and up 2400.0% on a QoQ basis from $1.0 million in Q2 2022.
Fennec Pharmaceuticals (FENC) Short term Debt (2021 - 2022) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 2 years of Short term Debt data on file, last reported at $25.0 million in Q4 2022.
- Quarterly Short term Debt rose 1263.88% year-over-year to $25.0 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $25.0 million (up 1263.88% YoY) and the FY2022 annual result came in at $25.0 million, up 1263.88% from the prior year.
- Short term Debt rose to $25.0 million in Q4 2022, from $1.0 million in the prior quarter.
- In the past five years, Short term Debt ranged from a high of $25.0 million in Q4 2022 to a low of $500000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 25.00 Mn |
| Jun 30, 2022 | 1.00 Mn |
| Mar 31, 2022 | 500,000.00 |
| Dec 31, 2021 | 1.83 Mn |
| Sep 30, 2021 | 1.83 Mn |
| Jun 30, 2021 | 2.00 Mn |